This model predicts the risk of resistance to antipseudomonal beta-lactams among respiratory and bloodstream isolates of Pseudomonas aeruginosa and other non-fermenting gram-negative bacilli (NFGN) such as Acinetobacter baumanii, etc.
It is particularly useful in critically-ill patients with risk of infections due to P. aeruginosa or NFGN in the respiratory tract (ventilator-associated pneumonia) or bloodstream (prolonged hospitalization or severely immune compromised hosts with qSOFA score ≥2)
Select All Applicable Risk Factors
Antipseudomonal beta-lactams include piperacillin-tazobactam, ceftazidime, cefepime, meropenem, and imipenem
Resistance to any of these agents confers beta-lactam resistant P. aeruginosa